NBIX:NASDAQ
Neurocrine Biosciences, Inc
$167.40
arrow_downward
-1.18%(-2.00) 1D
Nov 13, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
$169.96
High
$171.16
Low
$164.65
Mkt. cap
16.94B
Avg. vol.
1.41M
Volume
1.38M
P/E ratio
24.83
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.74
Beta
0.36
Shares outstanding
101.22M
No. of employees
2K
Open
$169.96
High
$171.16
Low
$164.65
Mkt. cap
16.94B
Avg. vol.
1.41M
Volume
1.38M
P/E ratio
24.83
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.74
Beta
0.36
Shares outstanding
101.22M
No. of employees
2K
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
Stock market today: Dow, S&P 500, Nasdaq futures edge higher after wholesale inflation grows, Nvidia stock rebounds
Nasdaq
·
1 day ago
Chartstopper: November 13, 2026
Bloomberg.com
·
8 hours ago
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteneurocrine.com